Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) Director Matthew L. Posard sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the transaction, the director now directly owns 109,755 shares […]
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) Director Matthew L. Posard sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the transaction, the director now directly owns 109,755 shares […]
Scout Investments Inc. decreased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 261,483 shares of the biopharmaceutical company’s stock after selling 4,095 shares during the period. Scout Investments Inc. owned about 0.20% of Halozyme […]
Epoch Investment Partners Inc. raised its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 250.5% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 1,163,033 shares of the biopharmaceutical company’s stock after buying an additional 831,199 shares during the quarter. Epoch Investment Partners Inc.’s holdings in Halozyme Therapeutics were worth $42,986,000 […]
Evoke Wealth LLC purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 36,657 shares of the biopharmaceutical company’s stock, valued at approximately $1,355,000. A number of other […]